Item type |
学術雑誌論文 / Journal Article(1) |
公開日 |
2012-12-04 |
タイトル |
|
|
タイトル |
Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL |
言語 |
|
|
言語 |
eng |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
philadelphia chromosome-positive acute lymphoblastic leukemia |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
imatinib |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
allogeneic hematopoietic stem cell transplantation |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
prognostic factor |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
著者 |
Mizuta, Shuichi
Matsuo, Keitaro
Maeda, Tomoya
Yujiri, Toshiaki
Hatta, Yoshihiro
Kimura, Yukihiko
Ueda, Yasunori
Kanamori, Heiwa
Usui, Noriko
Akiyama, Hideki
Takada, Satoru
Yokota, Akira
Takatsuka, Yoshifusa
Tamaki, Sigehisa
Imai, Kiyotoshi
Moriuchi, Yukiyoshi
Miyazaki, Yasushi
Ohtake, Shigeki
Ohnishi, Kazunori
Naoe, Tomoki
|
抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enrolled in the JALSG Ph+ALL202 study, 97 patients obtained complete remission (CR) by imatinib-combined chemotherapy, among whom 60 underwent allo-HSCT in their first CR. The probabilities of overall survival (OS) and disease-free survival (DFS) at 3 years after HSCT were 64% (95% CI, 49–76) and 58% (95% CI, 43–70), respectively. Prognostic factor analysis revealed that the major BCR–ABL transcript was the only unfavorable predictor for OS and DFS after HSCT by both univariate (HR, 3.67 (95% CI 1.49–9.08); P=0.005 and HR, 6.25 (95% CI, 1.88–20.8); P=0.003, respectively) and multivariate analyses (HR, 3.20 (95% CI, 1.21–8.50); P=0.019 and HR, 6.92 (95% CI, 2.09–22.9); P=0.002, respectively). Minimal residual disease status at the time of HSCT had a significant influence on relapse rate (P=0.015). Further study of the BCR–ABL subtype for the clinical impact on outcome of allo-HSCT in Ph+ALL is warranted. |
書誌情報 |
Blood Cancer Journal
巻 2,
号 5,
p. e72,
発行日 2012-06
|
出版者 |
|
|
出版者 |
Macmillan Publishers Limited |
EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
20445385 |
DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1038/bcj.2012.18 |
権利 |
|
|
権利情報 |
© 2012 Macmillan Publishers Limited All rights reserved 2044-5385/12 |
権利 |
|
|
権利情報 |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Blood Cancer Journal, 2(5), e72; 2012 |